WO2011045760A3 - Micronized olmesartan medoxomil compositions - Google Patents
Micronized olmesartan medoxomil compositions Download PDFInfo
- Publication number
- WO2011045760A3 WO2011045760A3 PCT/IB2010/054641 IB2010054641W WO2011045760A3 WO 2011045760 A3 WO2011045760 A3 WO 2011045760A3 IB 2010054641 W IB2010054641 W IB 2010054641W WO 2011045760 A3 WO2011045760 A3 WO 2011045760A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- micronized
- compositions
- olmesartan medoxomil
- medoxomil
- olmesartan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising micronized particles of olmesartan medoxomil and processes thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2119DE2009 | 2009-10-13 | ||
IN2119/DEL/2009 | 2009-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011045760A2 WO2011045760A2 (en) | 2011-04-21 |
WO2011045760A3 true WO2011045760A3 (en) | 2012-01-05 |
Family
ID=43413907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/054641 WO2011045760A2 (en) | 2009-10-13 | 2010-10-13 | Micronized olmesartan medoxomil compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011045760A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2554159A1 (en) * | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
WO2014002011A1 (en) * | 2012-06-26 | 2014-01-03 | Micro Labs Limited | Micronized particles of olmesartan medoxomil and pharmaceutical composition thereof |
WO2014030082A1 (en) | 2012-08-22 | 2014-02-27 | Lupin Limited | Novel method to obtain olmesartan medoxomil with reduced particle size |
CN103263395A (en) * | 2013-06-10 | 2013-08-28 | 南京正宽医药科技有限公司 | Telmisartan tablet preparation and preparation method thereof |
JP6653116B2 (en) * | 2014-08-27 | 2020-02-26 | 日本ケミファ株式会社 | Olmesartan prodrug formulations |
JP2017008018A (en) * | 2015-06-19 | 2017-01-12 | 日本ジェネリック株式会社 | Olmesartan medoxomil tablet in which elution properties are improved |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281800A1 (en) * | 2005-04-12 | 2006-12-14 | Glenmark Pharmaceuticals Limited | Polymorphic form of olmesartan and process for its preparation |
WO2007128478A2 (en) * | 2006-05-04 | 2007-11-15 | Lek Pharmaceuticals D.D. | Pharmaceutical composition |
CA2681591A1 (en) * | 2007-03-23 | 2008-10-02 | Daiichi Sankyo Company, Limited | Pulverized crystals of olmesartan medoxomil |
WO2009113420A1 (en) * | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | Improvement of dissolvability of preparation containing olmesartan medoxomil |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
WO2007047838A2 (en) | 2005-10-20 | 2007-04-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing olmesartan medoxomil |
-
2010
- 2010-10-13 WO PCT/IB2010/054641 patent/WO2011045760A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281800A1 (en) * | 2005-04-12 | 2006-12-14 | Glenmark Pharmaceuticals Limited | Polymorphic form of olmesartan and process for its preparation |
WO2007128478A2 (en) * | 2006-05-04 | 2007-11-15 | Lek Pharmaceuticals D.D. | Pharmaceutical composition |
CA2681591A1 (en) * | 2007-03-23 | 2008-10-02 | Daiichi Sankyo Company, Limited | Pulverized crystals of olmesartan medoxomil |
WO2009113420A1 (en) * | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | Improvement of dissolvability of preparation containing olmesartan medoxomil |
EP2253318A1 (en) * | 2008-03-13 | 2010-11-24 | Daiichi Sankyo Company, Limited | Improvement of dissolvability of preparation containing olmesartan medoxomil |
Also Published As
Publication number | Publication date |
---|---|
WO2011045760A2 (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
WO2011098582A3 (en) | Novel crystalline forms of ivabradine hydrochloride | |
EP2251038A4 (en) | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both | |
ZA201008379B (en) | Glucocorticoid mimetics,methods of making them,pharmaceutical compositions,and uses thereof | |
WO2012042371A3 (en) | Pharmaceutical composition | |
IL224288A (en) | Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
IL214425A (en) | Substituted bicyclic heterocyclic compounds, pharmaceutical compositions comprising them and uses thereof | |
IL215799A (en) | Quinazolone compounds, pharmaceutical compositions comprising the same and uses thereof | |
IL216254A (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof | |
SI2373681T1 (en) | Pharmaceutical compositions of albiglutide | |
EP2136634A4 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
IL210997A (en) | Compositions for the treatment of mrsa and uses thereof for the preparation of medicaments | |
IL210549A (en) | Substituted- quinoxaline-type bridged-piperidine compounds, compositions comprising them and uses thereof for the manufacture of medicaments | |
EP2447253A4 (en) | Dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof | |
MX2011014019A (en) | Diazahomoadamantane derivatives and methods of use thereof. | |
WO2012068441A3 (en) | Intedanib salts and solid state forms thereof | |
WO2013134534A3 (en) | Solid state forms of cabazitaxel and processes for preparation thereof | |
WO2009115084A3 (en) | Pyrrolopyrimidine derivatives, and use thereof | |
WO2011045760A3 (en) | Micronized olmesartan medoxomil compositions | |
WO2011041311A3 (en) | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods | |
IL217057A0 (en) | Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
WO2014068586A3 (en) | Solid oral compositions of tolvaptan | |
WO2012075015A3 (en) | Oral metronidazole pharmaceutical compositions | |
WO2010065586A3 (en) | Preparation of capecitabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10782690 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10782690 Country of ref document: EP Kind code of ref document: A2 |